PGEN Stock Overview
Operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Precigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.90 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.77 |
| Beta | 1.68 |
| 11 Month Change | -3.66% |
| 3 Month Change | -22.16% |
| 1 Year Change | -20.80% |
| 33 Year Change | -77.71% |
| 5 Year Change | -83.58% |
| Change since IPO | -96.35% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate
Feb 28
Precigen: RRP Targeting With AdenoVerse Technology Platform
Jan 20Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?
Nov 04Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?
Jul 18Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade
May 15Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio
Apr 18Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
Nov 10Precigen names Rutul Shah as chief operating officer
Sep 21Circling Back On Precigen
Aug 23Is Precigen (NASDAQ:PGEN) Using Too Much Debt?
Aug 10Precigen Q2 2022 Earnings Preview
Aug 07Precigen to sell Trans Ova Genetics for $170M upfront
Jul 05Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?
May 10Shareholder Returns
| PGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.3% | -6.5% | -1.0% |
| 1Y | -20.8% | 14.6% | 30.3% |
Return vs Industry: PGEN underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: PGEN underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| PGEN volatility | |
|---|---|
| PGEN Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PGEN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PGEN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 202 | Helen Sabzevari | precigen.com |
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.
Precigen, Inc. Fundamentals Summary
| PGEN fundamental statistics | |
|---|---|
| Market cap | US$245.04m |
| Earnings (TTM) | -US$139.56m |
| Revenue (TTM) | US$3.96m |
66.7x
P/S Ratio-1.9x
P/E RatioIs PGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGEN income statement (TTM) | |
|---|---|
| Revenue | US$3.96m |
| Cost of Revenue | US$53.07m |
| Gross Profit | -US$49.11m |
| Other Expenses | US$90.46m |
| Earnings | -US$139.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | -1,239.14% |
| Net Profit Margin | -3,521.68% |
| Debt/Equity Ratio | 0% |
How did PGEN perform over the long term?
See historical performance and comparison